Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 30
1993 165
1994 261
1995 275
1996 328
1997 406
1998 385
1999 416
2000 495
2001 530
2002 515
2003 521
2004 476
2005 534
2006 512
2007 529
2008 523
2009 563
2010 607
2011 654
2012 707
2013 709
2014 677
2015 757
2016 686
2017 743
2018 776
2019 818
2020 769
2021 707
2022 654
2023 596
2024 752
2025 864
2026 446

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,429 results

Results by year

Filters applied: . Clear all
Page 1
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Cortés J, et al. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19. N Engl J Med. 2025. PMID: 41124233 Clinical Trial.
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X; ENGOT-ov65/KEYNOTE-B96 investigators. Colombo N, et al. Lancet. 2026 Apr 18;407(10538):1525-1537. doi: 10.1016/S0140-6736(26)00602-1. Epub 2026 Apr 10. Lancet. 2026. PMID: 41974150 Clinical Trial.
Paclitaxel.
Zhang Y, Shi J, Fernie AR. Zhang Y, et al. Curr Biol. 2026 Mar 23;36(6):R238-R240. doi: 10.1016/j.cub.2026.01.058. Curr Biol. 2026. PMID: 41875857
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.
Schmid P, McArthur HL, Cortés J, Xu B, Cardoso F, Casalnuovo M, Demirci U, Freitas-Junior R, Ghosh J, Hegg R, Iwata H, Karnaukhov I, Chuken YL, Nechaeva M, Robson ME, Villalobos-Valencia R, Yamashita T, Zurawski B, de Bruin EC, Grinsted L, D'Cruz C, Foxley A, Park YH. Schmid P, et al. Ann Oncol. 2026 May;37(5):650-662. doi: 10.1016/j.annonc.2025.12.012. Epub 2025 Dec 19. Ann Oncol. 2026. PMID: 41422862 Free article. Clinical Trial.
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagaméri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB. Lorusso D, et al. Lancet. 2026 Apr 18;407(10538):1513-1524. doi: 10.1016/S0140-6736(26)00462-9. Epub 2026 Apr 10. Lancet. 2026. PMID: 41974149 Free article. Clinical Trial.
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
Harter P, Trillsch F, Okamoto A, Reuss A, Kim JW, Rubio-Pérez MJ, Vardar MA, Scambia G, Trédan O, Nyvang GB, Colombo N, Bidziński M, Grimm C, Lheureux S, Van Nieuwenhuysen E, Heitz F, Wenham RM, Nishio S, Lim MC, Marquina G, Altundağ Ö, Bergamini A, Sabatier R, Wimberger P, Gold MA, Sehouli J, Park-Simon TW, Kent E, Correa A, Aghajanian C; DUO-O Investigators. Harter P, et al. Ann Oncol. 2026 Apr;37(4):503-520. doi: 10.1016/j.annonc.2025.11.020. Epub 2025 Dec 9. Ann Oncol. 2026. PMID: 41380962 Free article. Clinical Trial.
17,429 results
You have reached the last available page of results. Please see the User Guide for more information.